Lotus Pharmaceuticals Co., Ltd (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795)today announced that it made a voluntary donation of 10,000 packs chloroquine phosphate to Thai Ministry of Public Health to assist local government with possible solutions to COVID-19.
“As an industry, we are at the frontline in looking to support the world during this time of need,” commented by Robert Wessman, Chairman of Lotus and CEO and Executive Chairman, “with the outbreak of the Coronavirus, our daily lives are changing. We are constantly monitoring developments to understand how we can continue to manage the situation both internally and externally. Nothing is more important to us than the safety of our employees and all of our customers and communities we work with around the world.”
Lotus has been proactively monitoring changes and developments and taking all measures to mitigate any interruption since the outbreak. It has created procedures to ensure the health and safety of the employees to make sure that the team can continue to operate at the capacity needed, especially in its manufacturing sites in both Taiwan and Korea, and tracks the process on regular and ad hoc basis.
“We have been coordinating plans around business continuity to minimize the impact and to continue to serve its patients, customers and communities who rely on us, around the world. We are ensuring our supply chains are unaffected, so we can continue to operate, making sure we deliver our products to everyone who needs them. We have built contingency supplies to make sure that we can continue to deliver on our promise. With the network of customers we have built, local teams are able to continue to serve patients in each market efficiently.” Wessman added.
Lotus is an Alvogen Company with high-value, complex generic products specializing in oncology, CNS, CVS, women health, and anti-obesity drugs. Headquartered in Taiwan, Lotus has been building commercial platforms across APAC since Alvogen’s majority investment in 2014 and successfully transformed to be Alvogen’s regional hub in Asian markets. In addition to its current direct markets in Taiwan and Korea, Lotus is also developing SEA markets, including Thailand and Vietnam, by consolidating Alvogen’s local infrastructure to offer more resourceful services on a well-established platform in all countries across the region. By aligning the Company’s internal best-in-class development and manufacturing capabilities, Lotus aims to benefit patients, its employees and shareholders alike.